Jenner Law: 30+ Years Fighting Big Pharma
More than 22,000 people living with HIV have filed lawsuits against Gilead Sciences in the state of California alleging that Gilead withheld a safer HIV treatment drug from them.
Gilead released a version of Tenofovir called TDF that Gilead sold under the brand names Truvada®, Atripla®, Viread®, Stribild®, and Complera® These drugs had known kidney and bone side effects. The lawsuit alleges that Gilead had a safer version of the drug called TAF that would have reduced the risk of kidney and bone injuries. The lawsuit alleges further that Gilead delayed the release of the safer drug for more than a decade in order to make them billions of dollars in excess profits.
In October 2019, the Superior Court for the State of California has named Rob Jenner Co-Lead Counsel in the California Coordinated Proceeding of Gilead Tenofovir Cases (JCCP No 5043). The first case is set for trial on July 11, 2022.
Jenner Law is currently investigating claims on behalf of HIV patients who have developed kidney disease or bone density loss after taking any of these drugs.
Rob Jenner has more than three decades experience as a leader in national lawsuits against major drug companies, and was an early courtroom advocate for better treatments for HIV and AIDS patients. He is the author of Transfusion-Associated AIDS, a legal treatise for lawyers handling AIDS related personal injury claims. He is the former Chair of the AIDS Litigation Group of the American Association for Justice, and has lectured internationally on the legal rights of persons impacted by HIV/AIDS. Mr. Jenner has been repeatedly selected by federal and state court judges to lead teams of plaintiffs’ attorneys in complicated, multi-district legal battles against some of the nation’s most powerful pharmaceutical and medical device companies. For the second year in a row, The National Trial Lawyers have named Rob Jenner one of America’s Top 50 Influential Trial Lawyers. The announcement was made in The Trial Lawyer magazine (Spring 2019).